BPC-157 and tissue repair: what the evidence actually supports.

The mechanism: VEGF and the nitric oxide system

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. Its healing properties were first documented in the gastrointestinal tract, where it exhibited cytoprotective effects across essentially every tissue type studied.

The primary mechanism involves upregulation of vascular endothelial growth factor (VEGF) expression at injury sites. VEGF drives angiogenesis — the formation of new blood vessels — which is the biological prerequisite for tissue repair. BPC-157 also modulates nitric oxide synthase, enhancing NO availability at injury sites and further accelerating fibroblast migration.

Preclinical evidence: exceptional

The animal-model literature on BPC-157 is among the most extensive in peptide pharmacology. Dozens of independent research groups across multiple countries have replicated core findings: accelerated tendon-to-bone healing, gut mucosal repair, reduction in inflammatory markers, and reversal of drug-induced organ damage.

A 2018 review by Seiwerth et al. in Current Pharmaceutical Design synthesized this body of work, concluding that BPC-157 consistently accelerates healing across tissue types with a favorable safety profile and no reported organ toxicity at studied doses in animals.

Human evidence: limited but promising

The honest assessment: BPC-157 has not been subject to large randomized controlled trials in humans. Small early-phase studies and case series exist, primarily from Croatian research groups. The compound has not completed Phase III trials for any indication. It is not FDA-approved.

This is why Nexphoria classifies BPC-157 as Tier B− (investigational). The preclinical signal is compelling enough that physicians include it in the formulary for appropriate patients — but the evidence-to-risk discussion with each patient is explicit, not assumed.

Who benefits: clinical use cases

In clinical practice, BPC-157 is used primarily in two contexts: soft-tissue injury recovery (tendon, ligament, muscle tears) and gastrointestinal protection during protocols that include compounds with GI side effects.

Typical protocol: 250–500 mcg subcutaneous daily or twice-daily, 8–12 weeks. Oral pH-stable formulations are available for GI-specific use. Monitoring is clinical — there is no validated serum biomarker for BPC-157 response, so symptom tracking and functional assessment are the primary endpoints.

Share

References

1. [1]Seiwerth S et al. BPC-157 and standard angiogenic growth factors: gastrointestinal tract healing, wound healing, and angiogenesis. Curr Pharm Des. 2018;24(18):1972-1989. Link
2. [2]Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. Link